We are thrilled to announce that MyoPax has been selected for the ProFIT funding program by the Investment Bank of Berlin (IBB) and the European Union (EFRE, European Fund for Regional Development).

Link to the funding initative: Profit // IBB

In this esteemed program, we are collaborating with the Clinic for Neurosurgery and the Clinic for Experimental Surgery at the Charité – Universitätsmedizin Berlin. This support will enable us to intensively work on expanding the clinical application fields for human muscle stem cells (PHSats) as advanced therapy medicinal products (ATMP).

🤝 A heartfelt thank you to the Investitionsbank Berlin and our cooperation partners at Charité, especially PD Dr. med. Nils Hecht and PD Dr. med. Karl Hillebrandt, for the fantastic collaboration thus far.

☝ This is a significant step forward towards translating innovation @ Charité and MDC: We are committed to advancing the development of therapies for diseases that currently have no or inadequate treatments options available.